# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew S. Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $35 price target.
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiop...
Jefferies analyst Amy Li assumes Liquidia (NASDAQ:LQDA) with a Buy rating and announces Price Target of $43.